Return-to-School Practices for Pediatric Hematopoietic Cell Transplantation Recipients during the COVID-19 Pandemic

Transplant Cell Ther. 2022 Jan;28(1):54.e1-54.e4. doi: 10.1016/j.jtct.2021.09.007. Epub 2021 Sep 17.

Abstract

Although organizations such as Centers for Disease Control and Prevention and American Academy of Pediatrics have published guidelines favoring the resumption of in-person schooling during the coronavirus disease 19 (COVID-19) pandemic, there is no specific guidance on hematopoietic cell transplantation (HCT) recipients' safe return to school. We conducted a cross-sectional survey of pediatric HCT physician members of the Pediatric Transplantation and Cellular Therapy Consortium practicing in the United States to describe current return-to-school practices during the COVID-19 pandemic for HCT recipients. A total of 122 respondents (response rate, 30.6%) from 60 transplant centers in 32 US states completed the survey. Most of the respondents (76%) recommended that HCT recipients consider a remote or hybrid school option at this time if possible. If not possible, the respondents recommended a return to in-person school if the patient is at least 12 months post-transplantation or off immune suppression, while taking school safety measures and local COVID-19 cases into account. These results provide valuable guidance for the HCT community, patients, and caregivers on important topics to consider while making return-to-school decisions.

Keywords: COVID-19; Hematopoietic cell transplantation; Return to school.

MeSH terms

  • COVID-19*
  • Child
  • Cross-Sectional Studies
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Pandemics
  • Pediatrics*
  • Return to School
  • SARS-CoV-2
  • Schools
  • United States